Cancers, Vol. 16, Pages 1493: Programmed Death 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Gene Expression in Peripheral Blood Mononuclear Cells Can Serve as Prognostic Biomarkers for Hepatocellular Carcinoma
In conclusion, PD-1 gene expression is associated with OS and PFS and CTLA-4 gene expression is associated with OS, whereas the serum biomarkers analyzed in this study show no significant correlation with survival in HCC. Hence, PD-1 and CTLA-4 expressed in PBMCs are considered potential prognostic biomarkers for patients with HCC that can facilitate prediction of malignancy, response to currently available HCC treatments, and overall survival. (Source: Cancers)
Source: Cancers - April 13, 2024 Category: Cancer & Oncology Authors: Ji Ah Lee Hei-Gwon Choi Hyuk Soo Eun Jiyoon Bu Tae Min Jang Jeongdong Lee Chae Yeon Son Min Seok Kim Woo Sun Rou Seok Hyun Kim Byung Seok Lee Ha Neul Kim Tae Hee Lee Hong Jae Jeon Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1494: Prediction of Overall Disease Burden in (y)pN1 Breast Cancer Using Knowledge-Based Machine Learning Model
Conclusions: The expert knowledge-based BN model predicted ongoing trial outcomes, validating reported results and assumptions. In addition, the model demonstrated the ODB in different arms, with an emphasis on quality of life. (Source: Cancers)
Source: Cancers - April 13, 2024 Category: Cancer & Oncology Authors: Seok-Joo Chun Bum-Sup Jang Hyeon Seok Choi Ji Hyun Chang Kyung Hwan Shin Division for Breast Cancer, Korean Radiation Oncology Group Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1495: XPC Protects against Carcinogen-Induced Histologic Progression to Lung Squamous Cell Carcinoma by Reduced Basal Epithelial Cell Proliferation
l Nasrallah
Lung squamous cell carcinoma (LUSC) is the second leading cause of lung cancer. Although characterized by high DNA mutational burdens and genomic complexity, the role of DNA repair in LUSC development is poorly understood. We sought to better understand the role of the DNA repair protein Xeroderma Pigmentosum Group C (XPC) in LUSC development. XPC knock-out (KO), heterozygous, and wild-type (WT) mice were exposed topically to N-nitroso-tris-chloroethylurea (NTCU), and lungs were evaluated for histology and pre-malignant progression in a blinded fashion at various time-points from 8–24 weeks. H...
Source: Cancers - April 13, 2024 Category: Cancer & Oncology Authors: Catherine R. Sears Huaxin Zhou Emily Hulsey Bea A. Aidoo George E. Sandusky Nawar Al Nasrallah Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1496: Influence of Certification Program on Treatment Quality and Survival for Rectal Cancer Patients in Germany: Results of 13 Certified Centers in Collaboration with AN Institute
Conclusions: The results of the present study indicate an improvement in terms of the treatment quality and outcomes in certified CrCCs, which is enforced by certification-specific aspects such as a more differentiated surgical approach, a lower rate of certain postoperative complications, and a multidisciplinary approach. Further prospective clinical trials are necessary to investigate the influence of certification in the treatment of CRC patients. (Source: Cancers)
Source: Cancers - April 13, 2024 Category: Cancer & Oncology Authors: Mihailo Andric Jessica Stockheim Mirhasan Rahimli Sara Al-Madhi Sara Acciuffi Maximilian D ölling Roland Siegfried Croner Aristotelis Perrakis Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1491: Induction of the Inflammasome Pathway by Tyrosine Kinase Inhibitors Provides an Actionable Therapeutic Target for Hepatocellular Carcinoma
Albert Morales
During the last decade, tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib have been standard systemic treatments for advanced hepatocellular carcinoma (HCC). Previous data associated sorafenib with inflammasome activation. However, the role of the inflammasome in sorafenib and regorafenib signaling has not been described in liver cancer patients. For this purpose, we analyzed inflammasome-related transcriptomic changes in a murine HCC model. Our data confirmed inflammasome activation after both TKI treatments, sharing a similar pattern of increased gene expression. According to human database ...
Source: Cancers - April 13, 2024 Category: Cancer & Oncology Authors: Anna Tutusaus Marco Sanduzzi-Zamparelli Loreto Boix Patricia Rider Silvia Sub ías Pablo Garc ía de Frutos Anna Colell Montserrat Mar í Mar ía Reig Albert Morales Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1485: Emerging Therapies for Glioblastoma
Megan Keniry
Glioblastoma is most commonly a primary brain tumor and the utmost malignant one, with a survival rate of approximately 12–18 months. Glioblastoma is highly heterogeneous, demonstrating that different types of cells from the same tumor can manifest distinct gene expression patterns and biological behaviors. Conventional therapies such as temozolomide, radiation, and surgery have limitations. As of now, there is no cure for glioblastoma. Alternative treatment methods to eradicate glioblastoma are discussed in this review, including targeted therapies to PI3K, NFKβ, JAK-STAT, CK2, ...
Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Stella Aim é Rios Stephanie Oyervides David Uribe Angelica Maree Reyes Victor Fanniel Jonathan Vazquez Megan Keniry Tags: Review Source Type: research
Cancers, Vol. 16, Pages 1487: The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients
This study highlighted the potential cardioprotective and anti-sarcopenic properties of vericiguat during anthracycline therapy. Human cardiomyocytes and primary skeletal muscle cells were exposed to doxorubicin (DOXO) with or without a pre-treatment with vericiguat. Mitochondrial cell viability, LDH, and Cytochrome C release were performed to study cytoprotective properties. Intracellular Ca++ content, TUNEL assay, cGMP, NLRP-3, Myd-88, and cytokine intracellular levels were quantified through colorimetric and selective ELISA methods. Vericiguat exerts significant cytoprotective and anti-apoptotic effects during exposure ...
Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Vincenzo Quagliariello Massimiliano Berretta Irma Bisceglia Ilaria Giacobbe Martina Iovine Vienna Giordano Raffaele Arianna Matteo Barbato Francesca Izzo Carlo Maurea Maria Laura Canale Andrea Paccone Alessandro Inno Marino Scherillo Domenico Gabrielli Ni Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1486: Overall Survival after Radiotherapy for Brain Metastases according to ECOG Status & mdash;A Prospective Study of 294 NSCLC Patients
This study reports a prospective observational study including consecutive 294 NSCLC patients with first-time BMs. Overall survival (OS) was calculated from the start of RT to death or last follow-up (1 June 2023). Overall, in the 294 included patients (median age 69 years), the median OS was 4.6 months; 2.5 months after WBRT (N = 141), and 7.5 months after SRT (N = 153). After WBRT, mOS was equally poor for patients with ECOG 2 (1.9 months) and ECOG 3–4 (1.2 months). After SRT, mOS for patients with ECOG 2 was 4.1 months; for ECOG 3 patients, mOS was 4 1.6 months. For NSCLC patients with ECOG 2 diagnosed wit...
Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Astrid Telhaug Karlsson Marianne Jensen Hjermstad Nina Aass Eva Skovlund Stein Kaasa Olav Erich Yri Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1488: A Matter of Margins in Oral Cancer & mdash;How Close Is Enough?
Cancers, Vol. 16, Pages 1488: A Matter of Margins in Oral Cancer—How Close Is Enough?
Cancers doi: 10.3390/cancers16081488
Authors:
Mateusz Szewczyk
Jakub Pazdrowski
Piotr Pieńkowski
Bartosz Wojtera
Barbara Więckowska
Paweł Golusiński
Wojciech Golusiński
In patients with oral cancer, the risk factors for local, regional, and distant recurrence according to margin status have not been well established. We aimed to determine the risk factors for recurrence by margin status and to identify a margin cut-off point for improved survival in patients with close margins. We retrospectively reviewe...
Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Mateusz Szewczyk Jakub Pazdrowski Piotr Pie ńkowski Bartosz Wojtera Barbara Wi ęckowska Pawe ł Golusiński Wojciech Golusi ński Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1483: Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment & mdash;In Vitro, In Vivo and Clinical Trials Literature Review
This article delves into the latest advancements in therapeutic strategies targeting components of the tumor microenvironment and pivotal hallmarks of cancer: deregulating cellular metabolism and the Warburg effect, acidosis and hypoxia, the ability to metastasize and evade the immune system, aiming to enhance treatment efficacy while mitigating systemic toxicity. Insights from in vitro and in vivo studies and clinical trials underscore the promising effectiveness and elucidate the mechanisms of action of these novel therapeutic interventions for TNBC, particularly in cases refractory to conventional treatments. The integr...
Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Anna Szulc Marta Wo źniak Tags: Review Source Type: research
Cancers, Vol. 16, Pages 1489: Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures
This study aimed to explore the availability and access to orphan drugs for rare cancers in Bulgaria for the period of 2020–2023. We cross-compared data from both the European Union and national public sources to evaluate the number of available and accessible orphan drugs for rare cancers, the delay from market authorization to reimbursement, the dynamics of public expenditures, and regional disparities in access across the country. We juxtaposed the main characteristics of oncological and non-oncological orphan drugs as well. Only 15 out of 50 oncological orphan drugs that were authorized by the European Me...
Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Kostadin Kostadinov Ivelina Popova-Sotirova Yuliyana Marinova Nina Musurlieva Georgi Iskrov Rumen Stefanov Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1477: Exploring the Language Used to Describe Older Patients at Multidisciplinary Cancer Conferences
bir M. H. Alibhai
Older adults with cancer often present with distinct complexities that complicate their care, yet the language used to discuss their management at multidisciplinary cancer conferences (MCCs) remains poorly understood. A mixed methods study was conducted at a tertiary cancer centre in Toronto, Canada, where MCCs spanning five tumour sites were attended over six months. For presentations pertaining to a patient aged 75 or older, a standardized data collection form was used to record their demographic, cancer-related, and non-cancer-related information, as well as the presenter’s specialty ...
Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Valerie S. Kim Anthony Carrozzi Efthymios Papadopoulos Isabel Tejero Thirisangi Thiruparanathan Nathan Perlis Andrew J. Hope Raymond W. Jang Shabbir M. H. Alibhai Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1478: Application of PET/MRI in Gynecologic Malignancies
ebecca Rakow-Penner
The diagnosis, treatment, and management of gynecologic malignancies benefit from both positron emission tomography/computed tomography (PET/CT) and MRI. PET/CT provides important information on the local extent of disease as well as diffuse metastatic involvement. MRI offers soft tissue delineation and loco-regional disease involvement. The combination of these two technologies is key in diagnosis, treatment planning, and evaluating treatment response in gynecological malignancies. This review aims to assess the performance of PET/MRI in gynecologic cancer patients and outlines the technical challe...
Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Sheida Ebrahimi Elin Lundstr öm Summer J. Batasin Elisabeth Hedlund Karin St ålberg Eric C. Ehman Vipul R. Sheth Negaur Iranpour Stephane Loubrie Alexandra Schlein Rebecca Rakow-Penner Tags: Review Source Type: research
Cancers, Vol. 16, Pages 1479: Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience
Conclusion: Supporting previous studies, bevacizumab demonstrated positive effects on hearing, tumor control, and symptoms in NF2-related schwannomatosis, albeit with common adverse events. Therefore, careful consideration of an appropriate management strategy is warranted. (Source: Cancers)
Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Jules P. J. Douwes Erik F. Hensen Jeroen C. Jansen Hans Gelderblom Josefine E. Schopman Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1480: Investigating the Role of SNAI1 and ZEB1 Expression in Prostate Cancer Progression and Immune Modulation of the Tumor Microenvironment
In this study, we investigated a primary cohort of intermediate-risk PCa (n = 51) using two NanoString profiling panels designed to study cancer progression and immune response. We identified differentially expressed genes (DEGs) and pathways associated with biochemical recurrence (BCR) and clinical risk. Confirmatory analysis was performed using the TCGA-PRAD cohort. Noteworthy DEGs included collagens such as COL1A1, COL1A2, and COL3A1. Changes in the distribution of collagens may influence the immune activity in the tumor microenvironment (TME). In addition, immune-related DEGs such as THY1, IRF5, and HLA-DRA were also i...
Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: William Lautert-Dutra Camila Morais Melo Luiz Paulo Chaves Francisco Cesar Sousa Cheryl Crozier Dan Dion Filipe S. Avante Fabiano Pinto Saggioro Rodolfo Borges dos Reis Leticia Fr öhlich Archangelo Jane Bayani Jeremy A. Squire Tags: Article Source Type: research
